Clinical Trial Update: Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered

View source ↗

Summary

Expanded Access for OKN-007 in patients with diffuse midline glioma (H3 K27-altered) and diffuse intrinsic pontine glioma is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Intrinsic Pontine Glioma
• Diffuse Midline Glioma H3 K27-altered

Drugs mentioned

• OKN-007

Snippet

Sponsor: Oblato, Inc. | Conditions: Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma | Status: NO_LONGER_AVAILABLE